Author/Authors :
Kahn, Ryan M. Department of Obstetrics and Gynecology - Weill Cornell Medicine - New York - NY, USA , Gordhandas, Sushmita Department of Obstetrics and Gynecology - Weill Cornell Medicine - New York - NY, USA , Chapman-Davis, Eloise Department of Obstetrics and Gynecology - Division of Gynecologic Oncology - Weill Cornell Medical College-New YorkPresbyterian Hospital - New York - NY , USA , Margolskee, Elizabeth Department of Pathology and Laboratory Medicine - Weill Cornell Medical College-New York Presbyterian Hospital - New York - NY, USA , Matrai, Cathleen Department of Pathology and Laboratory Medicine - Weill Cornell Medical College-New York Presbyterian Hospital - New York - NY, USA , Chadburn, Amy Department of Pathology and Laboratory Medicine - Weill Cornell Medical College-New York Presbyterian Hospital - New York - NY, USA , Ritchie, Ellen Division of Hematology and Oncology - Weill Cornell Medical College - New York - NY, USA
Abstract :
Myeloid sarcoma (MS) is a rare, extramedullary tumor consisting of immature white blood cells of myeloid lineage. MS is usuallyassociated with the concurrent diagnosis of acute myeloid leukemia (AML) but can also present in the absence of bone marrowdisease or at relapse of AML. MS of the gynecologic tract is exceedingly rare; however, it is hypothesized that it is likely moreprevalent than previously understood given postmortemfindings and persistence in preserved ovarian tissue. There is minimalliterature surrounding MS and extramedullary relapse with no clear guidelines. This is a case report of a 48-year-old womanwith MS involving the uterine corpus, fallopian tubes, and left ovary followed by a literature review. The overall aim is to reviewdata regarding leukemic immune evasion and sanctuary sites in order to raise awareness as this represents an important andunderrecognized hematologic malignancy in an often misdiagnosed, underrecognized site.
Keywords :
Acute Myeloid Leukemia Presenting , Myeloid Sarcoma , Predisposition , Gynecologic Tract , AML , Myeloid sarcoma (MS)